| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | Epothilone B | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |